Background
Bladder cancer is a major cause of morbidity and mortality worldwide, and with an expected 74,000 newly diagnosed cases and 16,000 deaths in United States in 2015 [
1]. Risk factors, such as genetic and molecular abnormalities, chemical or environmental exposures, and chronic irritation, may contribute to the development of bladder cancer [
2]. At diagnosis, more than 90 % of bladder cancer patients presents transitional cell carcinoma [
3]. Approximately 75 % of newly diagnosed bladder cancer cases appear as non-muscular invasive tumors, they have a high rate of recurrence and progression despite local therapy. The remaining 25 % of newly diagnosed cases are muscle invasive and need either radical surgery or radiotherapy but often still have poor prognosis despite systemic treatment [
4,
5].
As an essential tumor suppressor, wild-type p53 is often mutated or inactivated in bladder cancer, especially in muscular invasive tumors [
6,
7]. Moreover, independent of tumor grade, stage and lymph-node status, the expressing level of p53 has been implicated as an important predictor of recurrence, progression and survival of patients with bladder cancer [
8]. Additionally, alterations of the wild-type p53 play a crucial role in the carcinogenesis of bladder urothelial cancers [
9]. Therefore, gain-of-function manipulation of wild-type p53 would be an ideal target for inhibiting bladder cancer cells.
RNA activation (RNAa) is a recently discovered mechanism of gene activation at transcriptional level triggered by small double-stranded RNAs (dsRNAs), and this dsRNAs are termed as small activating RNAs (saRNAs) [
10]. What’s more, this novel gene positive regulation mechanism is conserved in at least mammalian cells [
11]. A previous study has shown that a candidate dsRNA (dsP53-285) targeting sequence position -285 relative to the transcription start sites (TSS) in the human p53 promoter significantly induced p53 expression in cells of non-human primates [
12]. As such, reactivation of p53 through RNAa may offer a promising new therapeutic strategy for bladder cancer.
However, whether dsP53-285 can induce wild-type p53 expression in human bladder cancer cells remains unknown. In the present study, we transfected dsP53-285 into bladder cancer cell lines T24 and EJ for 72 h, and examined the wild-type p53 expression. Our results showed that dsP53-285 had potent ability to inhibit bladder cancer cells proliferation and metastasis by modulating wild-type p53 expression.
Methods
dsRNAs and recombinant Lentivirus
All the RNA duplexes used in present study which possesses 2-nucleotide 3’ overhangs were chemically synthesized by RiboBio Co., Ltd. (Guangzhou, China). A small interfering RNA (siP53) was used to silence p53 expression and a dsControl which lacks significant homology to all known human sequences was used as a negative control [
10,
13]. Lenti-dsP53-285 and Lenti-dsControl were purchased from GenePharma (Shanghai, China). The sequences of all the custom dsRNAs are listed in Additional file
1: Table S1.
Cell culture, transfection with dsRNAs and infection with Lentivirus
The human bladder cancer cell lines T24 and EJ (ATCC) were cultured in RPMI 1640 medium (Hyclone, USA) supplemented with 10 % fetal bovine serum (Gibco, USA) in a humidified atmosphere with 5 % CO2 at 37 °C. The day before transfection, cells were trypsinized and plated to a new 6-well plate with growth medium at a density of 50-60 % without antibiotics. All dsRNAs were transfected at a final concentration of 50 nM by using Lipofectamine RNAiMax (Invitrogen, USA) according to the manufacturer’s instructions. Besides, dsRNA was replaced by MEM in mock transfection.
The day before infection, 3-5 × 103 cells were seeded in a 96-well plate with 100 μL culture medium, to ensure cells are at a density of 40-60 % in each well when infection. EJ cells were infected with Lenti-dsP53-285 or Lenti-dsControl according to the manufacturer’s protocol with modification. Culture medium was substituted 24 h later. Fluorescence expression was observed at 72-96 h after infection. Then cells were harvested and reseeded into new plates for further experiments.
RNA isolation and quantitative real-time PCR
Total cellular RNA was extracted from bladder cancer cells by using TRIzol reagent (Invitrogen, USA) according to the manufacturer’s protocol. After quantified by a Nano Drop ND-1000 spectrophotometer, 500 ng RNA was reversely transcribed into cDNA according to the instructions provided by Takara reverse transcription kit (Takara, China). The resulting cDNA was amplified by SYBR Premix Ex Taq II (Takara, China) conducted on the Mx3000P instrument (Stratagene, USA). All the primers included in this study were provided by Invitrogen (Shanghai, China) and listed in Additional file
1: Table S2. The relative expression of target genes’ mRNA was calculated with the 2
-ΔΔCt method. GAPDH was used as internal control. All experiments were done in triplicate.
Protein extraction and Western blotting analysis
All the cells were gathered and total proteins were extracted using RIPA lysis buffer supplemented with protease inhibitor Cocktail (Roche, Switzerland). Protein concentrations were calculated by using BCA protein assay kit (Beyotime, China). Equivalent amounts of protein samples (50 μg) were separated by 10 % sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene fluoride (PVDF) membranes. Nonspecific binding was blocked by incubating the PVDF membranes with 5 % bovine serum albumin (BSA) (Sigma-Aldrich, USA) for 2 h at room temperature. The membrane was then incubated with primary antibodies included p53 (1/1000) (Cell Signaling Technology, USA), p21 (1/2000) (Cell Signaling Technology, USA), Cyclin D1 (1/2000) (Affinity, USA), CDK4 (1/1000) (Affinity, USA), CDK6 (1/2000) (Affinity, USA), E-cadherin (1/1000) (BD Biosciences), β-catenin (1/500) (Boster, China), Vimentin (1/500) (Boster, China), ZEB1 (1/1000) (Cell Signaling Technology, USA), GAPDH (1/500) (Boster, China) and α-tubulin (1/500) (Boster, China) at 4 °C overnight. After several washes, the membranes were incubated with corresponding secondary antibody and detected by enhanced chemiluminescence (ECL) assay kit (Millipore, USA).
Cell proliferation assay
Cell proliferation was detected using the CellTiter 96® AQueous One Solution Cell Proliferation Assay kit (Promega, USA) according to the manufacturer’s protocol. Briefly, cells were transfected with indicated dsRNAs in a 6-well plate. The cells were trypsinized and seeded at 1000 cells/well into a new 96-well plate 24 h later. Cell growth was measured at daily interval from the next day to the fifth day. At each time point, 20 μl of CellTiter 96® AQueous One Solution was added to each well and incubated for 2 h at 37 °C. Absorbance was measured on a microplate reader (Bio-Rad, USA) at 490 nm.
Clonogenic survival assay
T24 and EJ cells were harvested 24 h after transfection of indicated dsRNAs. 1000 cells were reseeded in each new 6-well plate with complete medium for 10 days. The medium was replaced every 3 days to maintain the cells growth. The colonies were then fixed and stained with 0.5 % crystal violet (Sigma, USA) for 30 min at room temperature. The colony formation rate was calculated using the following equation: colony formation rate = number of colonies/number of seeded cells × 100 %.
Cell cycle analysis by flow cytometry
Cells were harvested 72 h after transfection and fixed with 70 % ethanol at 4 °C overnight. Then the cells were washed and incubated with RNase A (0.1 mg/mL) for 30 min at 37 °C. Cellular DNA was stained with propidium iodide (PI) (0.05 mg/mL) and analyzed on a FACSort flow cytometer (BD Biosciences, USA). All experiments were repeated 3 times and a total of 10,000 events were analyzed for each sample. The data were processed by CELL Quest software (BD Biosciences, USA).
Wound healing assay
After 72 h transfection, cells were trypsinized and counted. Approximate 5 × 105 cells were reseeded in each well of a new 6-well plate. With incubation overnight, the confluent cells monolayers were scratched with a 10 μL sterile pipette tip. Then the non-adherent cells were washed off with sterilized PBS and serum-free medium was added into the wells. The gap area caused by the scratch was monitored by the inverted microscope (Olympus, Japan). Three random non-overlapping areas in each well were pictured at 0 h, 12 h and 24 h post-scratch. Scratch width between the two linear regions was quantitated for assessing capacity of cells migration.
Migration and invasion assay
The 24-well Boyden chamber with 8 μm pore size polycarbonate membrane (Corning, USA) was used to analyze the cell motility. For invasion assay, the membrane was pre-coated with matrigel (BD Biosciences, USA) to form a matrix barrier. 2 × 104 cells, transfected with dsRNAs for 72 h, were seeded on the upper chamber with serum-free medium. Medium with 10 % serum was added to the lower chamber as a chemoattractant. The membranes were fixed at 24 h and stained with 0.5 % crystal violet (Sigma, USA). After removal of the non-motile cells at the top of the membranes with cotton swabs, 5 visual fields of 200× magnification of each membrane were randomly selected and counted.
In vivo tumorigenicity assay and experimental lung metastasis model
Equivalent amounts EJ cells (about 5 × 106, 200 μL) infected with Lenti-dsP53-285 or Lenti-dsControl were injected subcutaneously into the right back of male BALB/c-nude mice (Hua Fukang Biological Technology Co., Ltd, Beijing, China) at 4 weeks of age, respectively. Tumor length and width were measured using calipers every 4 days for 28 days. Tumor volume was calculated using the formula: V = length × width2 × 0.5. Animals were sacrificed 28 days after injection and tumors were weighed.
For in vivo metastasis assay, treated cells (2 × 105) were suspended in 100 μL of PBS and injected intravenously via the tail vein. At 30 days later after injection, the incidence and volume of metastases were estimated by imaging of mice for bioluminescence using the Living Image software (Xenogen, USA). The photon emission level was used to assess the relative tumor burden in the mice lungs. All nude mice were manipulated and cared according to NIH Animal Care and Use Committee guidelines in the Experiment Animal Center of the Tongji medical college of Huazhong University of Science and Technology (Wuhan, China).
Statistical analysis
All data were presented as the mean ± standard deviation (SD) for three independent experiments. Differences between groups were analyzed by t-tests using SPSS version 13.0 software (SPSS Inc., Chicago, IL, USA). P-value < 0.05 was considered to be statistically significant.
Discussion
In the present study, we identified a synthetic dsRNA (dsP53-285) exhibited considerable potency to activate wild-type p53 expression by targeting promoter in human bladder cancer T24 and EJ cells. Moreover, transfection of dsP53-285 induced the cells cycle arrest, impeded growth, migration and invasion. Besides, dsP53-285 could also significantly suppress the growth of bladder cancer xenografts and metastasis in nude mice. Several critical Cyclin-CDK genes (Cyclin D1 and CDK4/6) were down-regulated following transfection. And the EMT-associated genes (E-cadherin, β-catenin, ZEB1 and Vimentin) were also inversely expressed after dsP53-285 treatment. Most importantly, dsP53-285 inhibited bladder cancer cells growth and metastasis in vitro and in vivo mainly via manipulating wild-type p53 expression.
The activating effect of dsP53-285 molecules on p53 gene by targeting its promoter was initially discovered in African green monkey (COS1) and chimpanzee (WES) cells. Besides, dsP53-285 mediated up-regulation of p53 is conserved in mammalian cells [
12]. Therefore, non-human primate disease models may have promising clinical application for validating dsP53-285-based bladder cancer therapeutics.
It is important to point out that the kinetics of RNAa is different from traditional RNA interference. The activation emerges at approximate 48 h and the expressing level of targeted gene continues to increase by 72 h following transfection of specific dsRNA, and lasts for almost 2 weeks [
16,
17]. Our finding also showed that p53 expression mediated by dsP53-285 presented a time-course effect. These unique features of RNAa have been attributed to its nuclear nature and consequent epigenetic changes at targeted promoters [
10,
11,
16]. Consistent with previous studies, we examined the p53 expression at 72 h post dsP53-285 transfection [
18,
19]. What is more, this gene positively regulated phenomenon presents in a dose-dependent manner [
10,
20]. So according to other reports [
21,
22], we transfected the indicated dsRNAs at a final concentration of 50 nM in our research.
It is disappointed that the exact mechanism of RNAa remains largely unclear [
23,
24]. So far, selecting proper dsRNA target sites within specific gene promoter is still a hit-or-miss process [
11]. Hence, further studies are needed to improve the target prediction and facilitate to elicit preferable RNAa. In present study, we focus on exploring whether dsP53-285 possessed the ability to stimulate wild-type p53 expression in human bladder cancer cells other than non-human primates’ cells.
The p53 is a well-characterized tumor suppressor, encoded by the TP53 gene located on chromosome 17p13.1 [
25,
26]. Analysis of somatic DNA alterations of a recent study showed that nearly half of high-grade muscle-invasive bladder cancers had TP53 mutations and TP53 function was inactivated in 76 % patients [
6]. In addition, mutations of TP53 affect one allele, followed by the loss of the wild-type allele, finally disables the function of p53 completely [
27,
28]. Thus, reactivation or up-regulation of wild-type p53 would undoubtedly contribute to bladder cancer suppression. Accordingly, our findings strongly argued transfection of dsP53-285 into bladder cancer cells could inhibit their proliferation and metastasis through enhancing wild-type p53 expression.
Conclusions
Taken together, our study provides evidence that a synthetic dsP53-285 holds potent ability to activate wild-type p53 expression by targeting complementary motifs in promoter region of human bladder cancer T24 and EJ cells. Moreover, dsP53-285 inhibited bladder cancer cells proliferation and metastasis mainly via regulating p53 expression. Nevertheless, further researches are needed to clarify the exact RNAa mechanism and expand the application domain of dsP53-285 in tumor therapeutics.
Acknowledgments
This work was supported by the National Natural Science Foundation of China [grant number 81372759, China]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CW, QG and QZ performed the experiments and acquired data. ZC and JH designed the work, analyzed and interpreted the data, and drafted the manuscript. FL and ZY revised the manuscript. All authors have given final approval of the version to be published.